TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06588348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Description: All enrolled subjects will be prescribed a 14-day course of corticosteroid therapy in the form of Prednisone 20 mg to be taken once daily by mouth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal Manometry
Description: On the final day of Prednisone use, all subjects will undergo esophageal manometry testing to assess for treatment response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: All enrolled subjects will be asked to complete follow-up Eckardt and BEDQ surveys.
Study: NCT06593678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Program
Description: Participants in the intervention group will receive a home-based rehabilitation program delivered via an asynchronous digital telerehabilitation platform. The multimodal program is accessible at online platform and it is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet-based rehabilitation program
Description: Participants in the control group will receive a booklet-based rehabilitation program at home, provided through a detailed printed guide (explanatory booklet). This guide includes instructions in pictures and text for the multimodal program. It is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
Study: NCT05078047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced dose intensity of IO
Description: After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
Study: NCT06497543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Pemetrexed
Description: Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Pemetrexed
Description: Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
Study: NCT06331819

Intervention type: DIAGNOSTIC_TEST
Intervention: In-lab polysomnography
Description: Patient's brainwaves are recorded overnight to diagnose sleep disorder.

Intervention type: DEVICE
Intervention: Continuous positive airway pressure
Description: A machine that uses air pressure to keep breathing airways open while patients sleep.

Intervention type: DIAGNOSTIC_TEST
Intervention: Home sleep study device
Description: Patient's brainwaves are recorded overnight to diagnose sleep disorder.
Study: NCT06507774

Intervention type: DEVICE
Intervention: 3D Reconstruction Technology
Description: Utilization of 3D reconstruction technology to assist in preoperative planning and surgical procedures for thoracic surgery patients.

Intervention type: DEVICE
Intervention: No 3D reconstruction is used
Description: This group did not use 3D reconstruction for surgical navigation
Study: NCT04684836

Intervention type: OTHER
Intervention: Exposure to telemedicine, after the onset of the pandemic
Description: The exposure of interest was the switch to primary care telemedicine prompted by the COVID-19 epidemic
Study: NCT05757284

Intervention type: DIAGNOSTIC_TEST
Intervention: Lower Limb Lymhedema assessment
Description: assessessment with the selected measurement methods showing sufficient reliability and feasibility in the patient group with LLL from aim 1:NCT05269264. Measurement will occur at the genital/midline region, and on both legs/ feet.
Study: NCT05602246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transobturator cystocele repair
Description: Novel transvaginal surgical reconstruction of anterior compartment pelvic organ prolapse.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior colporrhaphy
Description: The traditional transvaginal surgery for cystocele treatment used as a comparator in the study
Study: NCT06215170

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SafeMedWaste
Description: SafeMedWaste opioid disposal kit
Study: NCT04944992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide 20 mg/mL
Description: Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 1.34 mg/mL
Description: Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
Study: NCT05148468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active spinal cord stimulation
Description: Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During active stimulation amplitude will be set to 90% paresthesia inducing threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham spinal cord stimulation
Description: Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During sham stimulation amplitude will be set to zero.
Study: NCT06245343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional inspiratory muscle training group
Description: Patients will be given fundamental inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, the training will be used as a home program.~In the 5th week, the functional inspiratory muscle training program will be started. Before the program begins, patients will be shown the exercises in the functional inspiratory muscle training program. Patients will be given functional inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, fundamental inspiratory muscle training will be used as a home program.~Pressure increases will be made weekly to 10 centimeters of water (cmH2O). Unsupervised training sessions will be followed by charts filled out by patients.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group will not be given any training during the 8-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
Study: NCT05816265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Iron Infusion Group
Description: Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
Study: NCT06245954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulated training
Description: Simulation training of bronchoscopists by means of simulators and extracorporeal lungs

Intervention type: OTHER
Group type: OTHER
Intervention: traditional bedside teaching
Description: TBLC training for bronchoscopists through traditional lectures, hands-on demonstrations
Study: NCT06397170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded repetitive arm supplementary program
Description: Patients in Group A will receive Graded repetitive arm supplementary program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task based training
Description: Patients in Group B will receive Task based training.
Study: NCT05920759

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cerebral blood flow
Description: Transcranial Doppler (TCD) is a non-invasive diagnostic tool used to estimate cerebral blood flow velocity (CBFV), cerebral autoregulation, cerebrovascular reactivity (CVR), intracranial pressure, cerebral perfusion pressure as well as other indicators of cerebral hemodynamics and autoregulation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cerebral blood flow
Description: Transcranial Doppler (TCD) is a non-invasive diagnostic tool used to estimate cerebral blood flow velocity (CBFV), cerebral autoregulation, cerebrovascular reactivity (CVR), intracranial pressure, cerebral perfusion pressure as well as other indicators of cerebral hemodynamics and autoregulation.
Study: NCT06492902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is conducted weekly in four weeks using patches (four sessions), each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. The patch with the needle will remain in place for one week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham auricular acupuncture
Description: Sham auricular acupuncture is conducted weekly for four weeks using patches (four sessions), each with a square shape and a side length of 10 mm. The patches will not contain any needles and will remain in place for one week.
Study: NCT04750525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: 120 BreEStim stimuli will applied for about 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: 120 BreEStim stimuli will applied for about 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EStim
Description: 120 EStim stimuli will applied for about 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EStim
Description: 120 EStim stimuli will applied for about 10 minutes.
Study: NCT05248074

Intervention type: OTHER
Group type: OTHER
Intervention: High-fat meal (over 900 kcal)
Description: High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
Study: NCT05558527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social support
Description: social support is provided in the form of social touch (hand holding)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social support
Description: social support is provided in the form of social touch (hand holding)
Study: NCT06298799

Intervention type: GENETIC
Group type: OTHER
Intervention: DNA Sequencing and Analysis
Description: DNA extracted from saliva / oral mucosa will be tested for diversities reported in the literature known to be associated with T2DM and Obesity and which may have a potential impact on the response to treatment with Semaglutide. In addition, the DNA will be screened for new diversities that have a potential impact on the response to treatment. working assumption of the study is that there can be 3 types of genetic variants that affect the drug's effectiveness and/or side effects.
Study: NCT05248074

Intervention type: OTHER
Group type: OTHER
Intervention: High-fat meal (over 900 kcal)
Description: High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.

Intervention type: DRUG
Group type: OTHER
Intervention: ABN401 (investigational product)
Description: The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.

Intervention type: DRUG
Group type: OTHER
Intervention: ABN401 (investigational product)
Description: The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
Study: NCT06298799

Intervention type: GENETIC
Group type: OTHER
Intervention: differential expression analysis with RNA-sequencing (RNA seq) experiments
Description: Performing small RNA sequencing experiments on an Illumina Next-Generation Sequencing (NGS) machine to investigate microRNAs (miRNAs) or other small non-coding RNAs involves specific steps tailored to the unique characteristics of these molecules
Study: NCT06314802

Intervention type: OTHER
Intervention: no intervention
Description: No intervention

Intervention type: OTHER
Intervention: no intervention
Description: No intervention

Intervention type: OTHER
Intervention: no intervention
Description: No intervention

Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study: NCT04041674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D02 DNA
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D02 DNA
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D02 DNA
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D02 DNA
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D02 DNA
Description: Administered by IM injection into the vastus lateralis
Study: NCT05026593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: IBI110 RP2D will be administered by IV infusion on Day 1 of each 21-day .
Study: NCT04909047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: parassacral transcutaneous electrostimulation
Description: Use of parassacral transcutaneous electrostimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: parassacral transcutaneous electrostimulation
Description: Use of parassacral transcutaneous electrostimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: parassacral transcutaneous electrostimulation
Description: Use of parassacral transcutaneous electrostimulation
Study: NCT05050318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation
Description: Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation
Description: Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Description: Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
Study: NCT05800080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
Description: one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
Description: one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal
Study: NCT05329948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptonomy application
Description: Feeling the fetus by touching the mother's womb with meditation
Study: NCT06160843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
Description: Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
Study: NCT04041674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B Vaccine
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B Vaccine
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B Vaccine
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B Vaccine
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B Vaccine
Description: Administered by IM injection into the vastus lateralis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B63521^11 gp120
Description: Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B63521^11 gp120
Description: Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IHV01 Protein
Description: Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
Study: NCT05024539

Intervention type: OTHER
Intervention: nonintervention

Intervention type: OTHER
Intervention: nonintervention
Study: NCT04230629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivinex XY1
Description: Implantation of an intraocular lens Hoya Vivinex XY1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivinex XY1A
Description: Implantation of an intraocular lens Hoya Vivinex XY1A
Study: NCT05247671

Intervention type: GENETIC
Intervention: ERCC1
Description: ERCC1 is a rate-limiting enzyme in the nucleotide excision repair pathway that is known to repair cisplatin-induced DNA damage. Polymorphisms in ERCC1 are known to affect response to cisplatin treatment. A mechanism explaining the effect of the ERCC1 polymorphism on the kidney may be that the homozygous carriers of this rs3212986 allele might have a greater capacity to repair cisplatin-induced DNA damage in their kidney epithelia, and thus would be more resistant to cisplatin-induced nephrotoxicity

Intervention type: GENETIC
Intervention: OCT2
Description: OCT2 is expressed on the basolateral membrane of Proximal Tubular Epithelial Cell (PTEC) and plays a central role in cisplatin uptake into tubular cells. Genetic variants in the cisplatin uptake transporter OCT2 showed association with the preservation of kidney function. Patients with the CT genotype in OCT2 polymorphism rs596881 exhibited positive changes in eGFR compared to individuals with the wild type CC genotype
Study: NCT05649215

Intervention type: OTHER
Intervention: No intervention will be applied.
Description: This is a questionnaire study.